ARTICLE | Regulation
FDA approves pair of sickle cell therapies with curative potential, but safety and pricing concerns cloud bluebird’s commercial path
By Lauren Martz, Executive Director, Biopharma Intelligence
December 9, 2023 1:07 AM UTC
![](https://platohealth.ai/wp-content/uploads/2023/12/two-sickle-cell-gene-therapies-enter-u-s-market-but-can-both-succeed.gif)
![](https://platohealth.ai/wp-content/uploads/2023/12/two-sickle-cell-gene-therapies-enter-u-s-market-but-can-both-succeed.jpg)
It was a landmark day for sickle cell disease patients. The decision by FDA to simultaneously approve Casgevy from partners CRISPR Therapeutics and Vertex and Lyfgenia from bluebird promises to transform the indication from a serious, painful, lifelong affliction to a potentially curable disease.
Doubts remain, however, about whether there’s opportunity in the market for both products…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/650865/two-sickle-cell-gene-therapies-enter-u-s-market-but-can-both-succeed